(Q46404441)

21 December 2017

title

Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas (English)

1 reference

21 December 2017

World Health Organization

main subject

1 reference

Marc C Chamberlain

1

1 reference

21 December 2017

Michael J Glantz

series ordinal

2

1 reference

21 December 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

21 December 2017

number of pages

6

1 reference

inferred from page(s)

published in

Cancer

1 reference

21 December 2017

volume

113

1 reference

21 December 2017

issue

8

1 reference

21 December 2017

page(s)

2146-2151

1 reference

21 December 2017

The natural history of asymptomatic meningiomas in Olmsted County, Minnesota.

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

Gamma knife radiosurgery of imaging-diagnosed intracranial meningioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

Temozolomide for treatment-resistant recurrent meningioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

Meningiomas: genetics, malignancy, and the role of radiation in induction and treatment. The Richard C. Schneider Lecture

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Epidemiology of intracranial meningioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Contemporary management of meningiomas: radiation therapy as an adjuvant and radiosurgery as an alternative to surgical removal?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Chemotherapy for meningiomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Recurrent meningioma: salvage therapy with long-acting somatostatin analogue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Salvage chemotherapy with CPT-11 for recurrent meningioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Cerebrospinal fluid-disseminated meningioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Hydroxyurea chemotherapy for unresectable or residual meningioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Interferon-alfa-2b for meningioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Treatment of high risk or recurrent meningiomas with hydroxyurea

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Adjuvant combined modality therapy for malignant meningiomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Bayesian two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Adaptive two-stage designs in phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Inhibition of the growth of cultured human meningioma cells by recombinant interferon-α

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Treatment of Neurotoxic Side Effects of Interferon-α with Naltrexone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23803

7 January 2021

Identifiers

DOI

10.1002/CNCR.23803

1 reference

21 December 2017

1 reference

21 December 2017